In pre-lambing vaccination programs for extensive sheep systems, the inactivated ovine E. coli antigen concentrate is incorporated into an aqueous aluminium hydroxide-adjuvanted suspension at a target inclusion of 12.0–18.0% v/v relative to final adjuvanted volume after potency is determined by relative potency assay and adjusted to 0.8–1.2 RP. The formulation vehicle consists of aluminium hydroxide gel at 2.0–3.0 mg Al³+/mL, thiomersal at 0.01% w/v, and phosphate-buffered saline with final pH 6.4–6.8; the aqueous antigen phase is filtered through a 0.22 µm polyethersulfone membrane before adsorption. Adsorption is carried out in a jacketed stainless steel vessel fitted with a top-entry agitator at 120–180 rpm for 18–24 h at 4°C; adsorption efficiency is confirmed by centrifugation at 3,000 × g for 10 min, with residual free antigen below 5% of total protein. The finished suspension is filled into multidose HDPE or PETG bottles of 100 mL and 250 mL under laminar airflow; downstream terminals are injectable suspensions for subcutaneous administration to ewes and does at 4–6 weeks pre-lambing. Batch release follows Ph. Eur. 0062, 9 CFR 113.64, and VICH GL3; sterility testing is performed according to Ph. Eur. 2.6.1, and endotoxin load is monitored by Limulus amebocyte lysate assay per Ph. Eur. 2.6.14. Freezing must be avoided because aluminium hydroxide flocculation is irreversible at −20°C; post-adsorption high-shear mixing above 500 rpm also reduces adsorption efficiency.

Batch-to-batch variance in aluminium hydroxide gel D50 values of 3–10 µm alters adsorption surface area and can shift free antigen from 2% to 8% when the concentrate is added at the upper 18.0% v/v limit; therefore, relative-potency-adjusted addition is used instead of fixed-volume addition. Mixing torque on a top-entry agitator increases above 1.5 N·m when the suspension temperature falls below 2°C, indicating incipient gel formation. Filling lines equipped with rotary piston pumps achieve fill-weight variation below ±1.0% at 100 mL fill volume; peristaltic pumps are not recommended because pulsation can shear the flocculated aluminium hydroxide lattice and increase free antigen content above the release limit.

What Emulsion Viscosity and Droplet Polydispersity Control Colostral Antibody Persistence in Goat Herds?

Water-in-oil emulsion vaccines prepared with the inactivated API use a 70/30 w/w oil-to-aqueous phase ratio when Montanide ISA 70 is selected; the aqueous antigen phase contains concentrated ovine/caprine E. coli antigen at 8–12% v/v of the aqueous phase, equivalent to 20–30% w/w of total emulsion. The oil phase is composed of mineral oil and mannide oleate emulsifier at 8–12% w/w of total formulation, and the aqueous phase is added under high-shear rotor-stator mixing at 6,000–8,000 rpm for 3–5 min. Droplet size is controlled by laser diffraction to a D50 of 1.5–3.0 µm and D90 ≤ 8.0 µm; viscosity at 20°C is maintained between 25–45 mPa·s to permit injection through a 16G needle without excessive backpressure. Terminal finished product types are 50 mL, 100 mL, and 250 mL polypropylene vials with bromobutyl stoppers; the emulsion must be filled by positive-displacement piston pumps because peristaltic pumps generate pulsation that can widen droplet size distribution. Stability is assessed after 6 months at 4°C and 12 months at 25°C; phase separation or coalescence above D90 10 µm triggers batch rejection. Compliance is governed by Ph. Eur. 0062, GMP Annex 15, and ISO 14644-1:2015; sterility of the aqueous phase is validated by membrane filtration, while the final emulsion cannot be sterile-filtered. Mixing with aluminium hydroxide-adjuvanted vaccines in the same syringe is contraindicated because ionic destabilization leads to immediate droplet coalescence.

Production-scale observation in ovine vaccine filling suites indicates that viscosity above 45 mPa·s at 20°C causes positive-displacement filler cavitation at speeds above 120 vials/min; reducing headspace pressure to −0.8 bar lowers cavitation but increases droplet coalescence when the emulsion is recirculated. Batch-to-batch variation in Montanide ISA 70 surfactant content influences droplet size more than rotor-stator speed alone; emulsification time is therefore adjusted by inline laser diffraction rather than fixed interval. Freeze-thaw cycling across −20°C and 25°C for 3 cycles causes D90 to shift beyond 10 µm, a condition that is used as a forced-degradation acceptance boundary during formulation development.

When a licensed clostridial–colibacillosis vehicle is submitted for batch release in early-lactation dairy sheep flocks, the formulation order differs from monovalent aqueous adsorption because Clostridium perfringens type C and D toxoids and tetanus toxoid compete with E. coli antigen for aluminium hydroxide binding sites. Sequential adsorption is used: clostridial toxoids are first adsorbed onto aluminium hydroxide at pH 6.0–6.3 for 12 h, followed by addition of the ovine E. coli antigen concentrate at 14.0–18.0% v/v with low-shear agitation at 100–150 rpm. Tetanus toxoid is then added at 8–12% v/v; the final aluminium load is 2.0–2.5 mg Al³+/mL. This order is necessary because F5/F41 fimbrial antigens show reduced adsorption when added after tetanus toxoid has occupied the highest-affinity binding sites. The blended suspension is held at 4°C for 18 h before filling; final pH is 6.0–6.3. Terminal finished types are 100 mL and 250 mL multidose LDPE bottles sealed with bromobutyl rubber stoppers. Release standards include 9 CFR 113.64 for the E. coli fraction, Ph. Eur. 0062, and VICH GL3 stability; batch potency is verified by agglutination titre or ELISA in vaccinated ewes. Antigenic competition is a known operational limitation: the E. coli F5/F41 agglutination titre can drop by up to 20–30% in combination formulations, requiring a higher inclusion ratio than in monovalent products. Incompatibility with thiomersal occurs when sodium metabisulfite residues from formalin neutralization exceed 0.05% w/v; therefore, the neutralizer is controlled by titration before preservative addition.

On production lines for combined clostridial–colibacillosis vaccines, the main bottleneck is the holding time between individual adsorptions, which adds 12–18 h to the batch cycle. Inline pH control at ±0.1 is required to prevent toxoid desorption; at pH below 5.8, aluminium hydroxide gel dissolves and releases Al³+ causing injection-site tissue irritation, while at pH above 6.8 the E. coli fimbrial antigens unfold and lose agglutination titre. Terminal filtration cannot be performed because the aluminium flocculated suspension blocks 0.22 µm membranes; sterility is assured by autoclaving all contact surfaces and aseptic assembly of the filling line.

Autogenous Bacterin Production Under Veterinary Prescription in Small Ruminant Practice

The regulatory pathway for autogenous ovine and caprine E. coli bacterins permits isolate-specific formulation when no licensed vaccine covers the outbreak serotype; in the United States this falls under 9 CFR Part 312, and in the European Union under Regulation (EU) 2019/6 autogenous vaccine provisions with national competent authority batch release. The isolated enterotoxigenic E. coli is expanded in a 50 L stirred bioreactor using tryptic soy broth at 37°C, pH 7.0–7.2, dissolved oxygen above 30% saturation; the culture is inactivated with formaldehyde at 0.3–0.5% v/v for 24 h at 37°C, followed by neutralization with sodium bisulfite at 0.1–0.2% w/v. Sterility of the inactivated suspension is confirmed by 14-day culture in thioglycollate and soybean-casein digest media. The formulation addition ratio for the autogenous concentrated antigen is 20–40% v/v of final volume, adjusted by agglutination titre and protein concentration to meet a prescribed dose volume of 2 mL for ewes and 1 mL for does. Terminal finished product types are 20 mL and 50 mL single-use vials, labelled with the prescribing veterinarian, farm identification, and batch number. The downstream production process does not include sterile filtration because whole-cell inactivated suspensions plug 0.22 µm membranes; instead, the entire filling train is steam-sterilized and the product is filled aseptically in a Grade A environment of an ISO Class 5 cleanroom. Operational boundaries include a 12-month shelf life at 2–8°C and restriction to the originating flock; cross-border shipment is prohibited in most jurisdictions without separate authorization.

A preservative-free single-dose injectable format complies with organic small ruminant herd health protocols.

For organic dairy sheep and goat systems where antimicrobial-free husbandry standards restrict preservative excipients, aseptic filling of single-dose preservative-free vaccines uses the inactivated antigen concentrate at 10–14% v/v in phosphate-buffered saline without thiomersal or phenol; final pH is 7.0–7.4 and osmolality is adjusted to 280–320 mOsm/kg. The manufacturing suite operates under EU GMP Annex 1 and ISO 14644-1:2015 Class A, with unidirectional airflow at 0.45 m/s ± 20%; the antigen concentrate is passed through a 0.22 µm PVDF filter immediately before filling because this format excludes adjuvants that would otherwise protect antigen integrity during storage. Terminal finished product types are 1 mL and 2 mL prefilled polypropylene syringes with 20G needles; each syringe is a single-dose unit, and no multidose presentation is produced. Sterility assurance level is maintained at ≤ 10⁻⁶ per Ph. Eur. 2.6.1; the absence of preservative means that any unused portion must be discarded after 24 h of first puncture if transferred to a multidose vial. Stability data support storage at 2–8°C for 18 months; exposure to 25°C for more than 72 h causes antigen aggregation above 1 µm and is not permitted. Compliance is referenced against Regulation (EU) 2019/6 and Ph. Eur. 0062.